222848-18-2

Upstream product

• 1142-20-7 N-Cbz-Ala 
• 222848-11-5 (S)-2-Amino-N-((S)-1-{(4R,5R)-5-[(S)-1-((S)-2-amino-3-methyl-butyrylamino)-3-methyl-butyl]-2,2-dimethyl-[1,3]dioxolan-4-yl}-3-methyl-butyl)-3-methyl-butyramide 
• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 137649-68-4 (4-benzyloxycarbonylamino-2,3-dihydroxy-1-isobutyl-6-methyl-heptyl)-carbamic acid benzyl ester 
• 142285-61-8 1-[5-(1-amino-3-methyl-butyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-3-methyl-butylamine 
• 142285-44-7 {1-[5-(1-benzyloxycarbonylamino-3-methyl-butyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-3-methyl-butyl}-carbamic acid benzyl ester 
• 142285-62-9 [(S)-1-((S)-1-{(4R,5R)-5-[(S)-1-((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-3-methyl-butyl]-2,2-dimethyl-[1,3]dioxolan-4-yl}-3-methyl-butylcarbamoyl)-2-methyl-propyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Development of a new type of protease inhibitors, efficacious against FIV and HIV variants

Based on the structural analysis of FIV protease and drug-resistant HIV proteases and molecular modeling, a new type of inhibitors with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as SIV and FIV. Modification of existing HIV protease inhibitors by reducing the size of the P3 residue has the same effect. This finding provides a new strategy for the development of HIV protease inhibitors effective against the wild-type and drug-resistant mutants. It further supports the use of FIV protease as a useful model for drug-resistant HIV proteases, which often have a more constricted binding region for the P3 group or the combined P3 and P1 groups.